When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
This presentation delves into the pathophysiology of CML, highlighting its progression from the chronic phase through the accelerated phase to the blast phase.…
Rajdeep Mysore, MD discusses melanoma, the most dangerous type of skin cancer. Originating from melanocytes, the color-producing cells in the skin, melanomas often appear as black or brown…
This presentation delves into the pathophysiology of CML, highlighting its progression from the chronic phase through the accelerated phase to the blast phase.
Preventing Respiratory Syncytial Virus (RSV), a common yet potentially severe infection, particularly among adults 65 and older or those with chronic health conditions is crucial.
Join Cathy from Level Up RN in this educational video where she explores Major Depressive Disorder (MDD) and other forms of depression. Cathy delves into the symptoms, risk…
Emma, a person who has IgA nephropathy, discusses her experience with diagnosis and treatment. She also discusses the importance of communication with medical professionals and she recommends avoiding…
Helen Rizos, PhD focuses on the clinical value of cell-free DNA in the management of melanoma. It highlights how circulating tumor DNA can be predictive and prognostic for…
Clarissa Tio, MD, a nephrologist at the University of Mississippi, moderates a discussion between Ariana Barton, a patient living with IgA nephropathy and a patient advocate, Joshua Samuels,…
Jonathan Barratt, MD, consultant nephrologist and professor of renal medicine, University of Leicester and John Walls Renal Unit, Leicester, provides a comprehensive overview of IgA nephropathy. Professor Barratt…
